Warm Autoimmune Hemolytic Anemia Market Summary

• The Warm Autoimmune Hemolytic Anemia market was valued at approximately USD 600 million in 2025 and is projected to reach nearly USD 2.4 billion by 2036, growing at a CAGR of 14.4% during the forecast period from 2026 to 2036.
• The Warm Autoimmune Hemolytic Anemia Market companies developing therapies include - Johnson & Johnson, Rigel Pharmaceuticals, Sanofi, Apellis Pharmaceuticals, Immunovant, Incyte Corporation, Zenas BioPharma, Bristol Myers Squibb, and others.

Warm Autoimmune Hemolytic Anemia Market and Epidemiology Analysis

• In 2025, the total number of diagnosed prevalent cases of wAIHA across the 7MM was estimated at approximately 88,000.
• The United States accounted for the largest share of diagnosed prevalent wAIHA cases in the 7MM, contributing around half (~50%) of the total disease burden.
• Currently, there are no marketed therapies specifically approved for wAIHA, highlighting a significant unmet medical need and creating opportunities for emerging targeted treatments to reshape the future therapeutic landscape.
• In February 2026, Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) seeking approval of IMAAVY (nipocalimab-aahu) as a potential first treatment for patients with wAIHA.

Factors Affecting the Warm Autoimmune Hemolytic Anemia Market Growth

Rising Prevalence of Autoimmune Disorders

The increasing incidence of autoimmune diseases and immune-related hematological conditions is contributing to the growing patient population affected by Warm Autoimmune Hemolytic Anemia (wAIHA), thereby driving market growth.

Advancements in Diagnostic Technologies

Improved diagnostic techniques, including advanced blood testing, direct antiglobulin testing (DAT), and better awareness among healthcare professionals, are enabling earlier and more accurate diagnosis of wAIHA.

Emergence of Novel Targeted Therapies

The development of innovative therapies such as FcRn inhibitors, BTK inhibitors, complement inhibitors, and monoclonal antibodies is transforming the treatment landscape and creating significant market expansion opportunities.

Increasing Research and Clinical Trial Activities

Growing investments in hematology research and the rising number of clinical trials evaluating targeted immunotherapies are accelerating the development of safer and more effective treatment options for wAIHA patients.

Request a sample to unlock the CAGR for " Warm Autoimmune Hemolytic Anemia Market Forecast "

DelveInsight's ‘Warm Autoimmune Hemolytic Anemia (wAIHA) – Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of the wAIHA, historical and forecasted epidemiology, as well as the wAIHA market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The wAIHA market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, wAIHA patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022–2036) across global regions. The report highlights key unmet medical needs in wAIHA and maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential.

Warm Autoimmune Hemolytic Anemia Disease Understanding

Warm Autoimmune Hemolytic Anemia Overview

Warm Autoimmune Hemolytic Anemia (wAIHA) is a rare autoimmune blood disorder in which the body’s immune system mistakenly produces antibodies that attack and destroy red blood cells at normal body temperature. This abnormal immune response leads to hemolysis, resulting in anemia and reduced oxygen delivery throughout the body. Common symptoms include fatigue, weakness, shortness of breath, dizziness, pale skin, jaundice, and an enlarged spleen. wAIHA may occur as a primary condition or secondary to other autoimmune diseases, infections, or certain medications.

Warm Autoimmune Hemolytic Anemia Diagnosis

The diagnosis of Warm Autoimmune Hemolytic Anemia involves a combination of clinical evaluation, laboratory testing, and assessment of hemolytic markers. The direct antiglobulin test (DAT or Coombs test) is the primary diagnostic tool used to detect antibodies attached to red blood cells. Additional blood tests, including complete blood count (CBC), bilirubin levels, lactate dehydrogenase (LDH), haptoglobin levels, and reticulocyte count, help confirm ongoing hemolysis and evaluate disease severity.

Warm Autoimmune Hemolytic Anemia Treatment

Treatment for Warm Autoimmune Hemolytic Anemia focuses on reducing immune-mediated destruction of red blood cells and managing anemia-related symptoms. Corticosteroids are typically considered first-line therapy, while immunosuppressive agents and monoclonal antibodies such as rituximab are commonly used in relapsed or refractory cases. In severe cases, blood transfusions, splenectomy, or emerging targeted therapies such as FcRn inhibitors, BTK inhibitors, and complement inhibitors may be utilized to improve disease control and patient outcomes.

Further details related to country-based variations are provided in the report.

Warm Autoimmune Hemolytic Anemia Epidemiology

Key Findings from Warm Autoimmune Hemolytic Anemia Epidemiological Analyses and Forecast

• In 2025, the total number of diagnosed prevalent cases of AIHA across the 7MM was estimated at approximately 120,000.
• In the United States, primary wAIHA accounted for around 20,500 diagnosed prevalent cases in 2025, while secondary wAIHA comprised approximately 22,200 cases.
• In 2025, females accounted for about 60% of diagnosed prevalent wAIHA cases across EU4 and the UK, while males represented around 40%.
• In 2025, across EU4 and the UK, the ≥65 age group accounted for around 55% of wAIHA cases, followed by the 45–64 age group at approximately 25%.
• In 2025, in Japan, severe wAIHA accounted for around 420 cases, while non-severe cases were estimated at approximately 600.

Warm Autoimmune Hemolytic Anemia Market Recent Developments and Breakthroughs

• In February 2026, Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the US FDA seeking approval of IMAAVY (nipocalimab-aahu) as a treatment for patients with wAIHA.
• According to the Novartis 2026 investor presentation, the Phase III data readout for ianalumab in wAIHA is anticipated in second half of 2026.
• In February 2026, the US FDA granted BTD to WAYRILZ (rilzabrutinib) for the treatment of patients with wAIHA. Additionally, Japan’s Ministry of Health, Labour and Welfare granted rilzabrutinib ODD for the same indication.

Warm Autoimmune Hemolytic Anemia Drug Analysis

The wAIHA drug chapter provides a detailed, market-focused review of current treatment options and the emerging pipeline across Phase I–III clinical trials. It covers key aspects such as mechanism of action, clinical trial data, regulatory updates, patents, collaborations, strategic partnerships, and upcoming catalysts for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into wAIHA treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the wAIHA therapeutics market.

Warm Autoimmune Hemolytic Anemia Marketed Drugs

IMAAVY (nipocalimab): Johnson & Johnson

Nipocalimab is an investigational monoclonal antibody that targets the neonatal Fc receptor (FcRn), inhibiting IgG recycling and reducing circulating pathogenic IgG antibodies. By lowering autoantibody levels, it has potential therapeutic benefits in IgG-mediated conditions such as warm autoimmune hemolytic anemia (wAIHA), where autoantibodies drive red blood cell destruction. Nipocalimab is currently being evaluated in a Phase II/III clinical trial for the treatment of warm wAIHA. In February 2026, Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) seeking approval of IMAAVY as a treatment for patients with wAIHA.

Warm Autoimmune Hemolytic Anemia Market Outlook

The wAIHA market is entering a phase of transformation after decades of relying on broad immunosuppression with corticosteroids, rituximab, and other nonspecific immunosuppressants. These treatments often provide temporary disease control but are associated with frequent relapse, steroid dependence, and cumulative toxicity. Despite the significant disease burden, there are currently no therapies specifically approved for wAIHA in most major markets, highlighting a substantial unmet medical need.

Key Findings from Warm Autoimmune Hemolytic Anemia Market Forecast Report

• In 2025, the wAIHA market across the 7MM was valued at approximately USD 600 million, reflecting a modest but growing market.
• The emerging pipeline is shifting the field toward mechanism-driven immune modulation, with late-stage candidates targeting key pathways involved in IgG-mediated hemolysis. Notable programs include IMAAVY (nipocalimab) from Johnson & Johnson, WAYRILZ (rilzabrutinib) from Sanofi, and ianalumab from Novartis.
• Overall, the emergence of targeted therapies and increasing recognition of disease burden are expected to drive steady growth in the 7MM wAIHA market from 2022–2036, with significant commercial potential for emerging pipeline treatments.
• In 2025, the United States accounted for the largest share of the wAIHA market within the 7MM, representing nearly 60% of the total market value.
• In 2036, among all the therapies for wAIHA, the highest revenue is estimated to be generated by IMAAVY, in the United States.
• The entry of late-stage candidates such as IMAAVY, Ianalumab, and WAYRILZ is expected to intensify competition in the second half of the forecast period.

Warm Autoimmune Hemolytic Anemia Competitive Landscape

The competitive landscape of Warm Autoimmune Hemolytic Anemia (wAIHA) is rapidly evolving, driven by a high unmet medical need and the absence of any widely approved disease-specific therapies. The market is currently transitioning from conventional off-label immunosuppressive treatments toward targeted biologics and mechanism-based therapies that aim to improve long-term disease control and safety outcomes.

Key Warm Autoimmune Hemolytic Anemia Market Companies

The Warm Autoimmune Hemolytic Anemia Market companies developing therapies include -

• Johnson & Johnson,
• Rigel Pharmaceuticals,
• Sanofi,
• Apellis Pharmaceuticals,
• Immunovant,
• Incyte Corporation,
• Zenas BioPharma,
• Bristol Myers Squibb, and others.

Further details will be provided in the report….

Warm Autoimmune Hemolytic Anemia Drugs Uptake

This section focuses on the uptake rate of potential Warm Autoimmune Hemolytic Anemia (WAIHA) therapies expected to be launched in the market during 2024–2036. The adoption of emerging therapies will depend on the evolving WAIHA competitive landscape, clinical efficacy and safety outcomes, pricing strategies, reimbursement availability, and order of market entry. Key WAIHA companies developing novel therapies through pivotal and confirmatory clinical studies must carefully design trial endpoints and comparator strategies to enhance regulatory success, accelerate approvals, and support rapid market uptake across the 7MM.

Warm Autoimmune Hemolytic Anemia Clinical Trial Activities

The WAIHA pipeline report provides comprehensive insights into ongoing and completed clinical trials across Phase III, Phase II, and early-stage development. The report highlights major WAIHA companies involved in developing innovative therapeutics targeting B-cell modulation, FcRn inhibition, complement pathway regulation, and immune system control to improve hemolysis management and patient outcomes.

Warm Autoimmune Hemolytic Anemia Pipeline Development Activities

The WAIHA clinical trial analysis report covers detailed information regarding strategic collaborations, mergers and acquisitions, licensing agreements, partnerships, regulatory milestones, and patent activities associated with emerging WAIHA therapies. The report also evaluates pipeline expansion strategies and recent advancements adopted by pharmaceutical and biotechnology companies operating within the WAIHA treatment landscape.

Latest KOL Views on Warm Autoimmune Hemolytic Anemia

To understand the real-world treatment landscape and evolving market trends, insights are gathered from Key Opinion Leaders (KOLs) and industry experts through primary research. These expert opinions help validate secondary research findings and provide a better understanding of current treatment approaches, patient reliance on conventional therapies such as corticosteroids and rituximab, therapy-switching patterns, accessibility challenges, and expected uptake of novel WAIHA therapies.

DelveInsight’s analysts interacted with multiple KOLs and subject matter experts across the 7MM to gain insights into the evolving WAIHA treatment environment. Their perspectives support the identification of unmet medical needs, emerging therapeutic opportunities, and the future impact of upcoming therapies on overall market dynamics.

Warm Autoimmune Hemolytic Anemia Drugs Market Qualitative Analysis

The WAIHA report performs qualitative and market intelligence analysis using analytical frameworks such as SWOT analysis and Conjoint Analysis. SWOT analysis evaluates strengths, weaknesses, opportunities, and threats associated with disease diagnosis, patient awareness, physician adoption, treatment accessibility, cost-effectiveness, and the overall WAIHA competitive landscape.

Conjoint Analysis assesses approved and emerging therapies based on important attributes including efficacy, safety profile, route of administration, dosing convenience, treatment adherence, and expected order of market entry. Therapies are scored across these parameters to evaluate their overall clinical and commercial potential.

Additionally, therapy safety and tolerability are assessed based on adverse events, long-term compliance, and patient acceptability observed during clinical trials. The analysis also incorporates probability of success and addressable patient population to determine the overall ranking and weightage of emerging therapies within the WAIHA market.

Warm Autoimmune Hemolytic Anemia Therapeutics Market Access and Reimbursement

The WAIHA therapeutics market report further provides detailed insights into country-wise market accessibility, reimbursement frameworks, and cost-effectiveness of currently available therapies. The report also highlights patient support programs, insurance coverage under public and private healthcare systems, reimbursement challenges, and initiatives aimed at improving patient affordability and access to advanced WAIHA therapies across the major markets.

Scope of the Warm Autoimmune Hemolytic Anemia Market Report

• The Warm Autoimmune Hemolytic Anemia Market report covers a segment of key events, an executive summary, a descriptive overview of wAIHA, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the wAIHA market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Warm Autoimmune Hemolytic Anemia Market report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM wAIHA market.

Warm Autoimmune Hemolytic Anemia Market Report Insights

• Warm Autoimmune Hemolytic Anemia (wAIHA) Patient population forecast
• Warm Autoimmune Hemolytic Anemia (wAIHA) therapeutics market size
• Warm Autoimmune Hemolytic Anemia (wAIHA) pipeline analysis
• Warm Autoimmune Hemolytic Anemia (wAIHA) market size and trends
• Warm Autoimmune Hemolytic Anemia (wAIHA) market opportunity (Current and forecasted)

Warm Autoimmune Hemolytic Anemia Market Report Key Strengths

• Epidemiology‑based (Epi‑based) bottom‑up forecasting
• Artificial Intelligence (AI)-enabled market research report
• 11-year forecast
• Warm Autoimmune Hemolytic Anemia (wAIHA) market outlook
• Patient Burden trends (by geography)
• Warm Autoimmune Hemolytic Anemia (wAIHA) Treatment addressable Market (TAM)
• Warm Autoimmune Hemolytic Anemia (wAIHA) Competitve Landscape
• Warm Autoimmune Hemolytic Anemia (wAIHA) major companies Insights
• Warm Autoimmune Hemolytic Anemia (wAIHA) Price trends and analogue assessment
• Warm Autoimmune Hemolytic Anemia (wAIHA) Therapies Drug Adoption/Uptake
• Warm Autoimmune Hemolytic Anemia (wAIHA) Therapies Peak Patient Share analysis

Warm Autoimmune Hemolytic Anemia Market Report Assessment

• Warm Autoimmune Hemolytic Anemia (wAIHA) Current treatment practices
• Warm Autoimmune Hemolytic Anemia (wAIHA) Unmet needs
• Warm Autoimmune Hemolytic Anemia (wAIHA) Clinical development Analysis
• Warm Autoimmune Hemolytic Anemia (wAIHA) emerging drugs product profiles
• Warm Autoimmune Hemolytic Anemia (wAIHA) Market attractiveness
• Warm Autoimmune Hemolytic Anemia (wAIHA) Qualitative analysis (SWOT and conjoint analysis)

FAQs

Warm Autoimmune Hemolytic Anemia Market Insights

• What was the wAIHA market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of wAIHA?
• What are the disease risks, burdens, and unmet needs of wAIHA? What will be the growth opportunities across the 7MM concerning the patient population with wAIHA?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of wAIHA? What are the current guidelines for treating wAIHA in the US, Europe, and Japan?

Reasons to Buy the Warm Autoimmune Hemolytic Anemia Market Forecast Report 

• The Warm Autoimmune Hemolytic Anemia Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the wAIHA market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.